Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2788144 | 1.00 | BLM (0.55) | BLMLMNAPTPN1ALOX15MEN1 | |
| SCHEMBL4826883 | 0.98 | BLM (0.52) | BLMLMNAPTPN1ALOX15MEN1 | |
| SCHEMBL8589919 | 0.98 | BLM (0.52) | BLMLMNAPTPN1ALOX15MEN1 | |
| SCHEMBL3573136 | 0.83 | BLM (0.55) | BLMLMNAPTPN1ALOX15MEN1 | |
| SCHEMBL16666684 | 0.83 | BLM (0.55) | BLMLMNAPTPN1ALOX15MEN1 | |
| Phytanic Acid SCHEMBL7889 | 0.80 | BLM (0.63) | BLMLMNAPTPN1ALOX15MEN1 | |
| SCHEMBL2356998 | 0.80 | BLM (0.63) | BLMLMNAPTPN1ALOX15MEN1 | |
| SCHEMBL2353062 | 0.80 | BLM (0.63) | BLMLMNAPTPN1ALOX15MEN1 | |
| SCHEMBL12713322 | 0.80 | BLM (0.57) | BLMLMNAPTPN1ALOX15MEN1 | |
| Phytanic Acid SCHEMBL3819827 | 0.80 | BLM (0.63) | BLMLMNAPTPN1ALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177345-A1 | PLATINUM-BASED AMPHIPHILE PRODRUGS | NanoMed Holdings Pty Ltd (AU) | 2025-06-05 | — | — | US | disclosed |
| US-12194014-B2 | Platinum-based amphiphile prodrugs | NanoMed Holdings Pty Ltd (AU) | 2025-01-14 | — | — | US | disclosed |
| EP-3296306-B1 | BASE-PROTECTED OLIGONUCLEOTIDE | AJINOMOTO KK (JP) | 2022-11-09 | — | — | EP | disclosed |
| EP-2816053-B1 | BASE-PROTECTED OLIGONUCLEOTIDE | AJINOMOTO KK (JP) | 2021-03-24 | — | — | EP | disclosed |
| CN-106977567-B | Oligonucleotide with protected base moiety | 味之素株式会社 | 2021-02-02 | — | — | CN | disclosed |
| EP-3296306-A1 | BASE-PROTECTED OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-03-21 | — | — | EP | disclosed |
| EP-3296306-A1 | BASE-PROTECTED OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9371353-B2 | Oligonucleotide with protected base | AJINOMOTO CO., INC. (JP) | 2016-06-21 | — | — | US | disclosed |
| US-9371353-B2 | Oligonucleotide with protected base | AJINOMOTO CO., INC. (JP) | 2016-06-21 | — | — | US | disclosed |
| US-9371353-B2 | Oligonucleotide with protected base | AJINOMOTO CO., INC. (JP) | 2016-06-21 | — | — | US | disclosed |
| US-8846885-B2 | Oligonucleotide with protected base | AJINOMOTO CO., INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| US-8846885-B2 | Oligonucleotide with protected base | AJINOMOTO CO., INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| US-20130267697-A1 | OLIGONUCLEOTIDE WITH PROTECTED BASE | AJINOMOTO CO., INC. (JP) | 2013-10-10 | — | — | US | disclosed |
| US-7846903-B2 | cubic liquid crystal formulation containing an amphiphilic compound such as 1-O-(5,9,13-trimethyltetradecyl)erythritol and a drug ( excluding a lysosomal enzyme) or cosmetic embedded in the cubic liquid crystal; time release agent | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20080113923-A1 | Type II Cubic Liquid Crystal Composition | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1813287-A1 | TYPE II CUBIC LIQUID CRYSTAL COMPOSITION | National Institute of Advanced Industrial Science and Technology (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-4871762-A | CARDIOVASCULAR DISORDERS, ANTIALLERGENS | SANKYO COMPANY, LIMITED (JP) | 1989-10-03 | — | — | US | disclosed |
| EP-0157603-B1 | 1, 3-BENZOXATHIOLE DERIVATIVES, THEIR USE AND THEIR PREPARATION | SANKYO COMPANY LIMITED (JP) | 1989-09-06 | — | — | EP | disclosed |
| US-4691027-A | FOR TREATING CICULATORY DISORDERS AND ALLERGIES | SANKYO COMPANY, LIMITED (JP) | 1987-09-01 | — | — | US | disclosed |
| EP-0157603-A2 | 1, 3-Benzoxathiole derivatives, their use and their preparation | SANKYO COMPANY LIMITED (JP) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12194014-B2 | Platinum-based amphiphile prodrugs | PHOSPHO1, ABCB4, CDIPT | BLM 670/4885LMNA 4280/4885PTPN1 3168/4885 |
| US-20250177345-A1 | PLATINUM-BASED AMPHIPHILE PRODRUGS | PHOSPHO1, ABCB4, CDIPT | BLM 693/4885LMNA 4270/4885PTPN1 3199/4885 |
| US-20080113923-A1 | Type II Cubic Liquid Crystal Composition | AQP1, AQP3, SCO2 | BLM 118/4885LMNA 1444/4885PTPN1 4309/4885 |
| US-20130267697-A1 | OLIGONUCLEOTIDE WITH PROTECTED BASE | POLRMT, POLN, RNGTT | BLM 367/4885LMNA 712/4885PTPN1 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.